Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-03-27 DOI:10.1016/j.vaccine.2025.127058

Veronika Vysotskaya , Martyna Gassowski , Amelia Kasper , Elena Gasich , Natalia Kolomiets , Alla Dashkevich , Kathleen Wannemuehler , Oleg Dubovik , Liudmila Mosina

{"title":"Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus","authors":"Veronika Vysotskaya , Martyna Gassowski , Amelia Kasper , Elena Gasich , Natalia Kolomiets , Alla Dashkevich , Kathleen Wannemuehler , Oleg Dubovik , Liudmila Mosina","doi":"10.1016/j.vaccine.2025.127058","DOIUrl":null,"url":null,"abstract":"<div><div>Belarus conducted a representative, national hepatitis B serosurvey to evaluate the impact of hepatitis B vaccination programme.</div><div>We used a multi-stage cluster design to select 3783 children born between 2009 and 2015. We collected demographic and immunization data, as well as venous blood samples, which were analysed for HBsAg by ELISA.</div><div>Out of 2870 participants with valid test results, one tested positive for HBsAg, resulting in a weighted seroprevalence of 0.02% (one-sided 95% upper bound = 0.09%). Of the 3731/3783 (99%) participants with immunization records, 86.8% (95% CI: 84.8; 88.6) had received a timely birth dose of hepatitis B vaccine and 85.6% (95% CI: 83.5; 87.4) had received a birth dose and at least two subsequent doses of the vaccine.</div><div>This study findings demonstrated the achievement of the regional hepatitis B control targets and significant progress toward the elimination of hepatitis B as a public health threat in Belarus.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"55 ","pages":"Article 127058"},"PeriodicalIF":4.5000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X2500355X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Belarus conducted a representative, national hepatitis B serosurvey to evaluate the impact of hepatitis B vaccination programme.

We used a multi-stage cluster design to select 3783 children born between 2009 and 2015. We collected demographic and immunization data, as well as venous blood samples, which were analysed for HBsAg by ELISA.

Out of 2870 participants with valid test results, one tested positive for HBsAg, resulting in a weighted seroprevalence of 0.02% (one-sided 95% upper bound = 0.09%). Of the 3731/3783 (99%) participants with immunization records, 86.8% (95% CI: 84.8; 88.6) had received a timely birth dose of hepatitis B vaccine and 85.6% (95% CI: 83.5; 87.4) had received a birth dose and at least two subsequent doses of the vaccine.

This study findings demonstrated the achievement of the regional hepatitis B control targets and significant progress toward the elimination of hepatitis B as a public health threat in Belarus.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.